A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Trial ID or NCT#

NCT04729751

Status

not recruiting iconNOT RECRUITING

Purpose

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome \[ALGS\] or Progressive Familial Intrahepatic Cholestasis \[PFIC\].

Official Title

Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome

Eligibility Criteria

Ages Eligible for Study: 0 Days to 364 Days
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
View All Criteria
Show Less

Investigator(s)

Noelle Hanako Ebel

View on ClinicalTrials.gov